Biochemical abnormalities in peripher, nerve are thought to precede and condition the development of diabetic neuropathy, but metabolic intervention in chronic diabetic neuropathy produces only limited acute clinical response. The residual, metabolically unresponsive neurological deficits have never been rigorously defined in terms of either persistent metabolic derangements or irreversible structural defects because (a) human nerve tissue is rarely accessible for anatomical and biochemical study and (b) experimentally diabetic animals do not develop the structural hallmarks of human diabetic neuropathy. Detailed neuroanatomical-functional-biochemical correlation was therefore undertaken in long-term spontaneously diabetic BB-Wistar rats that functionally and structurally model human diabetic neuropathy. Vigorous insulin replacement in chronically diabetic BB rats essentially normalized both the sural nerve fiber caliber spectrum and the decreased sciatic nerve myo-inositol and (Na,K)-ATPase levels generally associated with conduction slowing in diabetic animals; yet, nerve conduction was only partially restored toward normal. Morphometric analysis revealed a striking disappearance of paranodal axo-glial junctional complexes that was not corrected by insulin replacement. Loss of these strategic junctional complexes, which are thought to limit lateral migration of axolemmal Na channels away from nodes of Ranvier, correlates with and can account for the diminished nodal Na permeability and resultant nodal conduction delay characteristic of chronic diabetic neuropathy in this animal model.
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Introduction
Diabetic neuropathy reflects a complex interplay between disturbances in nerve metabolism induced by chronic insulin deficiency and/or hyperglycemia, and undefined independent genetic and/or environmental factors. Readily reversible defects in nerve metabolism in the diabetic rat directly contribute to reversible conduction slowing resembling that of early human diabetes (1, 2) . Although similar metabolic disturbances presumably condition the development of symptomatic neuropathy in susceptible diabetic patients, metabolic intervention produces only limited electrophysiologic or clinical response once diabetic neuropathy is clinically established (3, 4) . The structural and/ or biochemical lesions responsible for poorly reversible neurological deficits in diabetic patients, and the role of antecedent Receivedfor publication 21 May 1985. reversible functional and metabolic abnormalities in their development, remain unclear. The spontaneously diabetic BB rat exhibits both reversible nerve conduction slowing and subsequent structural lesions characteristic of human diabetic neuropathy (5) (6) (7) . It thereby provides a unique model in which to explore interrelationships between readily reversible and poorly reversible metabolic, functional and structural defects in diabetic peripheral nerve (5) (6) (7) .
Recent studies attribute nerve conduction slowing in diabetic rats to alterations in nerve Na and Na-related metabolism (8-1 1) . In the experimentally diabetic rodent, increased extracellular glucose concentration reduces nerve myo-inositol (MI)' content by competitive inhibition of Na-gradient-dependent MI uptake and/or increased polyol (sorbitol) pathway activity (8, 12, 13) . Nerve MI depletion in turn impairs nerve (Na,K)-ATPase (9, 14, 15) , probably via decreased protein kinase C activity reflecting diminished intracellular diacylglycerol and/or inositol-1,4,5-triphosphate release from inositol phospholipids ( 16) . Single-node voltage-clamp experiments in the acutely diabetic BB-Wistar rat ascribe the earliest and most readily reversible conduction slowing to a diminished nodal Na equilibrium potential attributable to impaired axonal (Na,K)-ATPase activity that selectively blocks conduction in the largest and most rapidly conducting myelinated nerve fibers (10, 1 1). Accompanying histologically demonstrated paranodal nerve fiber swelling has been attributed to elevated axonal Na concentrations (17, 18) . These electrophysiological and structural abnormalities are completely reversed by vigorous insulin treatment within the first 3 wk of diabetes (17, 18) . More prolonged hyperglycemia further slows nerve conduction by decreasing maximal nodal Na permeability (17, 18) by an unknown mechanism. Vigorous insulin treatment initiated 3 mo after the onset of diabetes in the BB rat completely corrects nerve MI content and (Na,K)-ATPase activity (and presumably the axolemmal Na-gradient), but nerve conduction velocity is only partially restored (15) . Therefore, additional poorly reversible structural and/or metabolic defects, possibly associated with persistently reduced nodal Na permeability, have been postulated (15) . The studies reported here examine nerve conduction, biochemistry, and morphometry in insulin-deficient and insulin-replaced chronically diabetic BB-Wistar rats with persistent slowing of nerve conduction. Nodes of Ranvier in large myelinated fibers were particularly scrutinized in an attempt to identify a structural basis for the persistently reduced nodal Na permeability thought to be responsible for poorly reversible conduction slowing in this animal model (17, 18) . Although the nerve fiber caliber spectrum in the insulin-replaced diabetics was virtually completely normalized, newly described structural Prediabetic BB-Wistar rats developed spontaneous diabetes at age 104+6 d, and were thereafter maintained persistently hyperglycemic for 12 wk on small daily doses of PZI insulin (0.5-3.0 U) until entry into the study protocol, at which time the above data were collected. At entry, diabetic rats were assigned in matched triplets to one of three groups: baseline diabetics were studied electrophysiologically as described in Methods, and then killed immediately for morphological studies. Insulin-deficient diabetics were studied electrophysiologically and then maintained hyperglycemic on small doses of PZI for the 6-wk study protocol. Insulin-replaced diabetics were begun on vigorous insulin treatment designed to normalize blood glucose values as described in Methods, Table II After 12-wk of insulin deficiency, diabetic rats were either continued hyperglycemic on small daily doses of PZI (insulin-deficient diabetics) or given insulin replacement therapy designed to normalize blood glucose (insulin-replaced diabetics) during the 6-wk study protocol as described in Methods and in Table I . Data were collected on the last day of the study protocol, after either 18 wk of insulin deficiency (insulin-deficient diabetics) or 12 wk of insulin deficiency followed by 6 wk of insulin replacement (insulin-replaced diabetics). (Na,K)-ATPase activity was assessed enzymatically in crude homogenates of sciatic nerve by comparing total ATPase activity in the presence and absence of Na and K ions as summarized in Methods and previously described in detail (9) . Similar values for (Na,K)-ATPase were obtained in these same nerve homogenates by comparing ATPase activity in the presence and absence of 0.10 mM ouabain (15) . These were published separately in detail (15) Quantitative morphometry: myelinated fiber size and distribution. Semi-thin (0.5 gm) toluidine-blue-stained transverse sections ofthe entire unifascicular sural nerve were photographed, and prints with a magnification of 1,000 times were used to calculate the area ofeach myelinated fiber with the aid of a 9872A digitizer interfaced with a 9825A desk computer and plotter (Hewlett-Packard Co., Cupertino, CA). Corresponding values for fiber diameters were calculated from the digitized areas, assuming the fibers were circular. The fascicular area ofeach nerve was digitized from photographic prints with a total magnification of 250 times. Myelinated fiber density per unit area and myelinated fiber occupancy (percent of the fascicular area occupied by myelinated fibers) were calculated as previously described (7). Axon-myelin ratio: Electronmicroscopic prints with a total magnification of 27,420 times were used to calculate the ratio between the natural logarithm of the axonal cross-sectional area and the corresponding myelin-sheath thickness expressed by the number of myelin lamellae. A mean of 47.2±3.7 fibers randomly chosen from each nerve were examined. Frequency of axoglial junctions: 358±40 terminal myelin loops were studied in each nerve for the presence ofaxo-glial junctions. Only terminal loops that contained clearly discernable double-layered membranes at the apposition of the axolemma to the myelin membrane were examined. The frequency of such myelin loops without axo-glial junctions in each paranodal area was compared with fiber diameter, and the percentage of loops without junctions in each animal was compared with MNCV by linear regression analysis.
Biochemical measurements: plasma and sciatic nerve MI. Plasma and sciatic nerve MI were determined gas-liquid chromatographically in protein-free Somogyi filtrates ofcardiac blood plasma or sciatic nerve Figure 1 . Effects of insulin deficiency and insulin replacement on hyperglycemia and growth in spontaneously diabetic BB-Wistar rats. After being maintained hyperglycemic and polyuric for 12 wk on small daily doses of insulin, BB-Wistar rats were divided into two treatment groups for the remaining 6 wk of the study protocol: insulin-deficient diabetics (solid lines, closed circles) were continued hyperglycemic on small daily doses of insulin, and insulin-replaced diabetics (broken lines, open triangles) were given larger replacement doses of insulin adjusted according to blood glucose measurements to achieve euglycemia as described in Methods and Tables I and II . Age-and sexmatched Wistars were used as nondiabetic controls (solid lines, open circles). Data shown here for the three subgroups (n = 5 in each) employed for morphological study did not differ significantly from those for the full groups employed for biochemical measurements at the beginning or the end of the 6-wk treatment protocol (compare with Tables I and II).
zymatic ATPase measurements or for gas-liquid chromatographic determination of MI content as previously described in detail (9) . Blood was aspirated from the left ventricle for analysis of serum osmolality by freezing point depression and pH (Radiometer, Copenhagen, Denmark). The right proximal sural nerve (opposite to the side on which MNCV was performed) was fixed in situ for 10 min by a 2.5% cacodylate-buffered (pH 7.40) glutaraldehyde fixative adjusted to an osmolality of 300 mosmol with sucrose. The proximal sural nerve was then carefully dissected, left in the same fixative for 4 h at 4VC, postfixed in 1% cacodylate-buffered osmium tetroxide (pH 7.40) for 2 h, dehydrated and embedded in Epon. Tables I   and II ).
homogenates as previously described (12, 20) . (Na,K)-ATPase activity: (Na,K-ATPase activity was measured enzymatically as (Na + K)-stimulated and ouabain-inhibited ATPase activities in freshly prepared crude homogenates of whole sciatic nerve as previously described in detail (8 computed by subtracting from this reaction rate the respective rates in the absence of NaCI and KCI or in the presence of 0.10 mM ouabain (8) .
Statistics. The results are presented as mean±SEM, and significance of difference was calculated by t test. Linear regression analysis was performed by the method of least squares. The comparison of myelinated fiber size distribution was performed using chi-square distribution and the individual size frequencies were compared using t test. (Table I) . Prediabetic rats (n = 21) developed diabetes at 104±6 d of age (range 89-131) and were persistently hyperglycemic (blood glucose 354±6 mg/ dl, n = 21) for 89±3 d before being entered into the three experimental groups. Body weight, blood glucose, and 24-h urine volume were similarly increased in all three experimental groups at the time of random assignment, and MNCV and EMPA were similarly decreased (Table I) .
Results

Development ofspontaneous diabetes
Insulin replacement therapy (Table II and Fig. 1 ). Vigorous insulin therapy progressively lowered and, after 6 wk, normalized plasma glucose levels in the insulin-replaced diabetics (Table II,  column 3) , and in the subgroup of insulin-replaced diabetics that underwent morphological assessment (Fig. 1, top panel) . Growth rate and 24-h urine volume were similarly normalized by insulin replacement therapy (Table II, columns 2 and 4, and Fig. 1 , middle and bottom panels). Small but significant differences in plasma osmolality (312±4 mosmol in insulin-deficient diabetics vs. 282±2 mosmol in nondiabetic controls) and pH (7.29±0.02 in insulin-deficient diabetics vs. 7.39±0.02 in nondiabetic controls) were also normalized by insulin replacement (287±3 mosmol and 7.38±0.02).
Electrophysiological measurements (Table II and Fig. 2 ). 6 wk of insulin replacement significantly improved MNCVs and EMPAs in the insulin-replaced diabetics (Table II, columns 5  and 6 ) and the similarly treated subgroup that was studied morphologically (Fig. 2, top and bottom panels) . MNCV remained essentially unchanged in both the nondiabetic controls and the 23% slower-conducting insulin-deficient diabetics, while increasing 21% in the insulin-replaced diabetics (compare Table  I, column 5, with Table II , column 5, and see Fig. 2, top panel) . However, MNCV in the insulin-replaced diabetics remained 1 1% below that of the nondiabetic control (Table II , column 5, and Fig. 2, top panel) . In contrast, EMPA was completely normalized by 6 wk of insulin replacement (Table II, column 6, Fig. 2,  bottom panel) . Thus, despite insulin replacement therapy that normalized plasma glucose and growth rate in diabetic rats, MNCV was only partially restored to normal.
Nerve MI and (Na,K)-ATPase (Table II) . Sciatic nerve MI in the insulin-deficient diabetics was reduced by 27% compared with the nondiabetic controls, and insulin replacement therapy raised nerve MI to that of the nondiabetic control (Table II,  column 7 ). (Na,K)-ATPase activity, as determined by (Na + K)-stimulation (Table II , column 8) or ouabain inhibition (data not shown) was reduced 24% in the insulin-deficient diabetic compared with the nondiabetic control. Insulin replacement raised (Na,K)-ATPase activity by 34%, so that it was no longer different from the nondiabetic control (Table II, 
column 8). Residual
ATPase activity in the presence of ouabain or in the absence of Na and K ions (i.e., non-(Na,K)-ATPase activity) was similar in all three treatment groups (data not shown). Therefore, in contrast to untreated streptozocin diabetes, spontaneous diabetes (treated with small maintenance doses of insulin) specifically influenced only (Na,K)-ATPase activity in sciatic nerve homogenates (15) . However, this defect was completely corrected by vigorous insulin replacement and therefore, the persistence of slowed MNCV in the insulin-replaced diabetics could not be explained on the basis of continued abnormalities in nerve MI metabolism or (Na,K)-ATPase activity (15) .
Qualitative morphology in sural nerve sections: transverse sections (Table III) . Marginated maloriented neurofilaments were encountered in <1% of myelinated axons in normal controls, and >3% of myelinated fibers in baseline, insulin-replaced (Fig. 3) . Sural nerve cross-sectional area, and myelinatedfiber density and number (Table IV) . There were no differences in total number of myelinated fibers, total fascicular area, or fiber density in sural nerve sections from insulin replaced, deficient, or baseline diabetics or the nondiabetic controls (Table IV) .
Myelinatedfiber size and distribution (Table IV, Figs. 4-7) .
Insulin-deficient rats exhibited a significant shift in sural nerve fiber caliber spectrum toward smaller fibers as compared with nondiabetic controls (P < 0.005) (Fig. 4) . This shift was due to .7 3c$ Semi-thin (0.5 gm) toluidine-blue-stained cross-sections of the entire unifascicular sural nerve from five animals in each group were photographed at a magnification of 1,000 times, and used to calculate total fascicular area, total area, number, and density of myelinated nerve fibers as described in Methods. a simultaneous decrease in the apparent frequency of large myelinated nerve fibers and an apparent increase in the frequency of small myelinated nerve fibers. Vigorous insulin replacement therapy increased large myelinated fibers without decreasing small myelinated fibers, which remained present in increased frequency (Fig. 5 ). Insulin-replaced diabetics differed from nondiabetic controls by a slightly but statistically significantly higher frequency of small myelinated fibers, whereas no difference was demonstrated in large-sized fibers (Fig. 6) . Thus, the overall fiber size distribution in the insulin-replaced diabetic was significantly shifted toward larger fiber size with respect to the insulin-deficient diabetic (P <0.005) ( Effect of 18 wk of insulin deficient diabetes on sural nerve myelinated fiber caliber spectrum. Sural nerves from five insulin-deficient diabetics and five nondiabetic controls were fixed, embedded, and stained for light microscopy as described in Methods. Fiber diameters were calculated from computer-assisted measurements of fiber areas made at a magnification of 1,000 times, assuming that all fibers were round. The height of each bar represents the mean percentage of fibers within each increment in fiber area or diameter, and the error bar represents SEM. The overall P value in the upper right was determined by chi-square analysis, and the significance of difference for each fiber size is indicated by the symbols above each pair of bars as determined by t test analysis (x = P < 0.01; xx = P < 0.005; and xxx = P < 0.001).
the basis ofan apparent increase in the smallest myelinated fibers (Fig. 6 ). Mean fiber area was significantly reduced in the insulindeficient diabetics compared with both the nondiabetic controls and the insulin-replaced diabetics (Table IV , column 1), and the slight difference between nondiabetic controls and insulinreplaced diabetics (Table IV, column 1) was attributable to the increase in small fibers (Fig. 6 ). Both the mean fiber area (Table  IV , column 1) and the fiber caliber spectrum (Fig. 7) were similar in insulin-replaced rats at the completion of the study and in the insulin-deficient diabetics at baseline. Thus, insulin deficiency detectably increased the frequency of small myelinated nerve fibers during the first 12 wk of diabetes, and decreased the frequency of large myelinated nerve fibers between weeks 12 and 18; insulin replacement therapy from week 12-18 prevented the decrease in large myelinated fiber frequency without significantly altering the preexisting increase in small myelinated nerve fiber frequency. Since MNCV primarily reflects conduction in the largest population ofmyelinated motor fibers (22) , the restoration ofnormal numbers oflarge myelinated nerve fibers in the insulinreplaced diabetics largely precludes a traditional morphometric explanation based on fiber caliber spectrum analysis for the persistently slowed MNCV in these animals. Axon-myelin ratio (Fig. 8) . Changes in the nerve fiber caliber spectrum can reflect either the appearance/disappearance of subpopulations of nerve fibers ofdiffering diameters, or changes in the size of preexisting nerve fibers. The relationship between axonal cross-sectional area and the number of lamellae in the associated myelin sheath is expressed by the equation log nat (axonal area) = k X (number of myelin lamellae) (7, 23) . When existing axons either shrink or swell, the number of myelin lamellae remains unchanged, thereby reflecting the preexisting axon size (7, 23, 24) . Therefore, the axon-myelin ratio (k in the above equation and b in Fig. 8 corresponding number of myelin lamellae for the four groups of animals studied (Fig. 8) . The axon-myelin ratio (regression coefficient b in Fig. 8 ) was significantly decreased in insulindeficient diabetics compared with both nondiabetic controls (P < 0.01) and insulin-replaced diabetics (P < 0.025) (Fig. 8) . No differences in axon-myelin ratio were found between nondiabetic controls and insulin-replaced diabetics, or between insulin-replaced diabetics and baseline diabetic rats (Fig. 8) . Thus axonal atrophy or shrinkage appears to have accounted for the decrease in myelinated fiber size that occurred in the insulin-deficient diabetics during the 6-wk study period (Fig. 4) . Since the decrease in the axon-myelin ratio between weeks 12 and 18 of insulin deficiency was prevented by insulin replacement, fiber shrinkage cannot provide a structural basis for persistently slowed MNCV in the insulin-replaced diabetics. Axo-glial junctional complexes (Fig. 9) . Terminal loops of myelin are normally attached to the axolemma by an array of junctional complexes that form a series of continuous circumferential bands around the axon in the paranodal region (25, 26) . Intact axo-glial junctions were detected in 94±1.2% of paranodal terminal myelin loops in nondiabetic controls, 72.7±1.4% insulin-deficient diabetics, and 80.4±3.0% in insulin-replaced diabetics. The frequency of myelin loops without axo-glial junctions (i.e., axo-glial dysjunction) was significantly higher in the insulin-deficient diabetics than in both the nondiabetic controls (P < 0.005) and the insulin-replaced diabetics (P < 0.025). However, the frequency ofaxo-glial dysjunction remained greater in the insulin-replaced diabetics than in the nondiabetic controls (P < 0.05). Normal axo-glial junctions were found in 83.4±2.8% of terminal myelin loops in baseline diabetics, which was not significantly different from insulin-replaced animals. Thus, insulin replacement halted the loss of further axo-glial junctions between weeks 12 and 18 ofinsulin deficiency, but did not restore those junctions lost before week 12.
Terminal myelin loops with axo-glial dysjunction were most prominent in large myelinated fibers of both insulin-deficient and insulin-replaced diabetics. Since these large fibers more directly affect MNCV, the frequency of axo-glial dysjunction was plotted against nerve fiber diameter. A mean of 14.1±2.0 randomly selected fibers in each nerve were investigated in this way. The frequency of axo-glial dysjunction increased significantly with fiber size in insulin-deficient (P < 0.005) and insulin-replaced diabetics (P < 0.05) and in the baseline diabetics (P < 0.05), but not in the nondiabetic controls (0.5 < P < 0.1). This relationship differed significantly between nondiabetic controls and the three diabetic groups, and between the insulinreplaced and insulin-deficient diabetic groups; no differences in this relationship could be demonstrated between insulin-replaced diabetics and the baseline diabetics (Fig. 9) .
Motor nerve conduction velocity and the frequency of axoglial dysjunction were negatively correlated in the insulin-replaced diabetics and nondiabetic controls (n = 10, r2 = 0. 
Discussion
In diabetic human beings and animals, slowing of nerve conduction both precedes and accompanies the development ofthe neuroanatomical lesions characteristic of diabetic neuropathy (3, (27) (28) (29) . The earliest detectable slowing of nerve conduction is readily reversible with metabolic intervention, and is attributed to reversible biochemical abnormalities in diabetic peripheral nerve (1) (2) (3) (4) 29 Axo-glial Dysjunction (%) Figure 10 . Relationship between MNCV and axo-glial dysjunction in nondiabetic controls (d), insulin-replaced diabetics (b), and insulin-deficient diabetics at baseline (c) and at the completion of the study (a (25, 26) . These structures are thought to maintain the characteristically high density ofaxolemmal intramembraneous particles within the nodal area by limiting their lateral migration into the adjacent internodal regions. Since these intramembranous particles probably correspond to voltage sensitive Na channels, their depletion from the node as a result of axo-glial dysjunction may account for the reduced nodal Napermeability and poorly reversible nerve conduction slowing in the chronically diabetic BB rat (Fig. 12 ) (26) . This notion is further supported by the inverse correlation of MNCV and axoglial dysjunction in the present study (Fig. 10) . The basis of the axo-glial dysjunction in rats replaced with insulin after 12 wk ofdiabetes has not been established. However, it may well represent persistent ultrastructural evidence of earlier paranodal swelling and its associated axo-glial spatial deformation (17) . However, no loss of axo-glial junctions is demon- strable after 6 wk of diabetes when paranodal swelling is still prominent (17) . Alternatively, axo-glial dysjunction may reflect independent underlying biochemical abnormalities that may or may not be involved in the earlier reversible conduction slowing and paranodal swelling. Galactocerebroside, a lipid element in axo-glial junctions (37) , is depleted from myelin isolated from the BB rat (38) . Membrane glycolipids are further implicated in chronic conduction slowing by studies in the spontaneously diabetic db/ db mouse, where ganglioside treatment selectively improves nerve conduction during the structural phase of diabetic neuropathy (39) . Lastly, altered membrane phosphoinositide composition, and/or associated changes in protein kinase C activity and/or inositol-(1,4,5)-tris-phosphate-mediated Ca mobilization might directly influence the integrity of axo-glial junctional complexes (40), as might other abnormalities in the endoneurial extracellular environment in diabetes (41) .
In summary, insulin deficiency initiates a series ofmetabolic alterations in diabetic peripheral nerve involving MI and the (Na,K)-ATPase, which can account for the early and reversible conduction block and paranodal swelling of large myelinated fibers in the BB rat. Continued insulin deficiency induces further poorly reversible structural damage, characterized by loss of axoglial junctions, that probably accounts for the poorly reversible impairment of nerve conduction in the chronically diabetic BB rat. Whether more prolonged insulin replacement would reverse even these more persistent abnormalities, or whether prevention of the MI-related (Na,K)-ATPase defect would prevent or delay their occurrence, remain subjects for future investigation. However, the pathogenetic sequence proposed in Figs. 11 and 12 offers a potential theoretical framework by which to explain the progressive development of less readily reversible nerve dysfunction in human diabetic neuropathy. Furthermore, the BB rat may provide a useful animal model in which to test therapeutic interventions such as aldose reductase inhibitors and/or MI or ganglioside supplementation for their ability to prevent or treat various biochemical, functional, and structural phases or elements of diabetic neuropathy. Finally, diabetic neuropathy is classically characterized as a primary disorder of either the axon or the Schwann cell (42) , whereas axo-glial dysjunction implies fundamental interactive abnormalities between both cell types in the region of the node of Ranvier.
